العربية
s

Cellular Therapeutics: New Options for Addressing Global Health Threats

February 10, 2019

13.30 - 13.50

DP World Hall


Share the Article
Facebook
Twitter
LinkedIn

Celularity is a development-stage company delivering allogeneic therapies from engineered cells and cell products derived from the human placenta, for applications in cancer immunology, and autoimmune and inflammatory diseases. These proprietary, placenta-derived allogeneic cells are immuno-compatible “universal donor” cells, from which Celularity is developing an on-demand suite of allogeneic cell therapy products. These products include novel placenta-derived natural killer (PNK) & cryopreserved PNK (CYNK) as well as genetically modified PNK/CYNK constructs. Celularity’s was the first allogeneic cancer immunotherapy used in human patients (August 2016) and has demonstrated competing results in early-stage human clinical trials in multiple myeloma and AML.